An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2 mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10 mg) in Japanese Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Voglibose
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 07 Apr 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 07 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2010 New trial record